Vilanterol

• COPD Maintenance
• Asthma Maintenance
• Chronic Bronchitis

Vilanterol is a long-acting beta-2 adrenergic agonist (LABA) with a 24-hour duration of action, available only as part of fixed-combination, once-daily Ellipta dry-powder inhalers. The combinations include Breo Ellipta (fluticasone furoate plus vilanterol), Anoro Ellipta (umeclidinium plus vilanterol), and Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol). These devices are used for maintenance treatment of COPD and, in the inhaled corticosteroid (ICS)-containing combinations, for maintenance treatment of asthma in adolescents and adults. Vilanterol is not sold as monotherapy because LABAs alone increase asthma-related death — a class-wide FDA boxed warning that drove the development of these fixed-combination inhalers. The Ellipta device platform's once-daily dosing simplifies regimens and may improve adherence compared with twice-daily inhalers, although the trade-off is less flexibility for patients who need finer titration.

Mechanism of Action

Vilanterol selectively activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase to increase intracellular cyclic AMP. Elevated cAMP activates protein kinase A, which phosphorylates regulatory proteins that lower intracellular calcium and relax airway smooth muscle, producing sustained bronchodilation. Unlike short-acting beta-agonists like albuterol, vilanterol's lipophilic side chain anchors it within the cell membrane near the receptor, prolonging the duration of action to a full 24 hours and supporting once-daily dosing. When combined with the long-acting muscarinic antagonist umeclidinium, the two bronchodilators act on complementary pathways (sympathetic activation and parasympathetic blockade) for greater bronchodilation than either alone — a particularly useful pairing in COPD, where both pathways contribute to airflow limitation. The fluticasone furoate component in Breo and Trelegy is a high-potency once-daily inhaled corticosteroid that suppresses airway inflammation, reduces eosinophil and lymphocyte activity, and decreases exacerbations. Vilanterol's onset of bronchodilation is within about 15 minutes, similar to formoterol and faster than salmeterol, although it is not used as a rescue inhaler.

Clinical Use

For COPD, the GOLD 2024 strategy recommends LABA plus LAMA combinations (such as Anoro) as first-line maintenance therapy in symptomatic patients at low exacerbation risk, and adds an inhaled corticosteroid (Trelegy or stepped therapy) for those with frequent exacerbations or eosinophilic inflammation (blood eosinophils above 300 cells/microliter). Alternatives include tiotropium plus a separate LABA, or salmeterol and formoterol-based combinations. For asthma, current Global Initiative for Asthma (GINA) guidance favors ICS-formoterol regimens for both maintenance and reliever use because of the rapid onset of formoterol, but ICS-vilanterol (Breo) is a reasonable once-daily alternative for adults with stable asthma not well controlled on ICS alone, particularly when adherence is a concern. Patients in St. Petersburg often need extra attention to environmental triggers — see our guide on managing asthma and COPD in the humid Florida climate for practical strategies, and our overview of year-round Florida allergies for the related rhinitis that often complicates lower airway disease. Vilanterol is never a rescue inhaler; patients always need a separate short-acting bronchodilator like albuterol for acute symptoms, and the rescue plan should be reviewed at each visit. Add-on therapies for severe asthma include biologics like omalizumab, mepolizumab, benralizumab, or dupilumab depending on phenotype.

How to Take It

The Ellipta inhaler delivers one inhalation once daily, taken at the same time each day. To use: open the cover with a single click (this arms the dose), exhale fully away from the mouthpiece, place the mouthpiece between your lips creating a tight seal, inhale steadily and deeply through the mouth, hold your breath for about 5-10 seconds, then exhale slowly. Close the cover. After each use, rinse your mouth with water and spit (do not swallow) to reduce the risk of oral thrush and hoarseness from the inhaled corticosteroid component. Store at room temperature in a dry place; the inhaler is good for up to 6 weeks after opening the foil tray, and the dose counter shows how many doses remain. If a dose is missed, take it as soon as you remember unless it is close to the next scheduled dose; do not double up. Bronchodilator effect begins within 15 minutes and persists 24 hours; patients on ICS-containing combinations may not see the full anti-inflammatory benefit for 1-2 weeks, with maximum benefit at 4-6 weeks. Continue your separate rescue inhaler exactly as instructed. If rescue inhaler use is increasing, that is a signal that the maintenance regimen needs adjustment — do not simply use more rescue inhaler.

Monitoring and Follow-Up

Reassessment every 3-6 months reviews symptom control (using validated tools like the Asthma Control Test or COPD Assessment Test), exacerbation frequency, inhaler technique (the most common reason for treatment failure — a brief in-office demonstration is invaluable), and adherence. Spirometry annually documents lung function trends, and pre- and post-bronchodilator testing helps distinguish asthma from COPD when the diagnosis is uncertain. Blood pressure and resting heart rate are checked because LABAs can produce mild tachycardia and modest blood pressure elevation, particularly in patients with cardiovascular comorbidity. Periodic potassium and glucose monitoring on comprehensive metabolic panels is appropriate, particularly in patients also on diuretics like furosemide or hydrochlorothiazide — beta-2 agonism shifts potassium intracellularly and can transiently raise glucose. Bone mineral density assessment is reasonable for patients on long-term moderate to high-dose inhaled corticosteroids, especially postmenopausal women. Annual influenza, current COVID-19, and age-appropriate pneumococcal vaccines (PCV20 or PCV15 followed by PPSV23) and the RSV vaccine for adults 60 and older are essential in chronic lung disease. Eye exams to screen for cataracts and glaucoma are recommended at baseline and periodically with chronic ICS use.

Special Populations

No dose adjustment is required for renal impairment. Severe hepatic impairment (Child-Pugh C) can substantially increase exposure of both vilanterol and fluticasone furoate; use with caution and monitor for systemic corticosteroid effects such as adrenal suppression or Cushingoid features. Older adults can use the standard regimen but warrant attention to cardiovascular effects, electrolyte changes, and bone health. Pregnancy data are limited; the benefits of well-controlled asthma generally outweigh theoretical fetal risks, since uncontrolled asthma during pregnancy carries clear risks to mother and fetus including preterm birth and growth restriction. Lactation: small amounts likely transfer; use is considered compatible with breastfeeding when needed. Pediatric: ICS-vilanterol (Breo) is approved down to age 5 in some regions for asthma, but most US labeling starts at 18 for COPD and varies for asthma; LABA/LAMA combinations are adult-only. Patients with severe milk-protein allergy should avoid the Ellipta inhaler because lactose is a component of the powder. Patients with cardiovascular disease, arrhythmias, hyperthyroidism, diabetes, or seizure disorders should be monitored closely.

When to Contact Your Doctor

Seek emergency care for sudden severe wheezing or chest tightness immediately after inhaling (paradoxical bronchospasm — discontinue and use rescue inhaler), rapid or irregular heartbeat, severe tremor, swelling of the face or throat, signs of severe asthma exacerbation (struggling to speak in full sentences, rescue inhaler not working, oxygen saturation below 92% on home pulse oximeter), or worsening breathlessness despite using your rescue inhaler. Call the office for white patches in the mouth (oral thrush), persistent hoarseness, increased rescue inhaler use (more than twice a week for asthma is a red flag), more frequent exacerbations, new vision changes (cataracts and glaucoma can develop with long-term inhaled corticosteroids), unexplained bruising, or symptoms that suggest adrenal suppression such as fatigue, weight loss, or low blood pressure on standing.

A few practical points distinguish patients who do well with vilanterol-containing inhalers from those who struggle. Inhaler technique is the single most fixable cause of poor outcomes — many patients have used inhalers for years without ever receiving formal coaching, and small adjustments (deeper inhalation, longer breath-hold, proper mouth seal) substantially improve drug delivery to the lower airways. Adherence is enhanced by once-daily dosing, but a missed dose still reduces protection and patients should establish a consistent routine. Patients with both asthma and COPD overlap (ACO) often benefit from triple therapy combinations like Trelegy that address both inflammation and bronchodilation. Living in St. Petersburg means dealing with seasonal triggers including pollen surges, mold from humidity, and air quality changes from prescribed burns or red tide events; awareness and proactive medication adjustment around predictable trigger periods can prevent exacerbations. Smoking cessation remains the single most important intervention for both COPD and asthma — even decades of smoking history, the lung function decline can be slowed by quitting, and rescue inhaler use typically falls within months. Finally, action plans (clear written instructions for when to step up therapy, start oral steroids, or seek emergency care) reduce hospitalization and should be reviewed and updated at every visit.

For a structured COPD or asthma action plan, inhaler technique review, vaccination status check, and individualized therapy selection — including whether vilanterol-containing combinations are right for your situation — contact us or schedule a visit at Zimmer Medical Group.